JP2024028453A5 - - Google Patents

Download PDF

Info

Publication number
JP2024028453A5
JP2024028453A5 JP2024002413A JP2024002413A JP2024028453A5 JP 2024028453 A5 JP2024028453 A5 JP 2024028453A5 JP 2024002413 A JP2024002413 A JP 2024002413A JP 2024002413 A JP2024002413 A JP 2024002413A JP 2024028453 A5 JP2024028453 A5 JP 2024028453A5
Authority
JP
Japan
Prior art keywords
pharma
acceptable salt
ceutically acceptable
rnai agent
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024002413A
Other languages
English (en)
Japanese (ja)
Other versions
JP7843302B2 (ja
JP2024028453A (ja
Filing date
Publication date
Priority claimed from JP2020543533A external-priority patent/JP7420727B2/ja
Application filed filed Critical
Publication of JP2024028453A publication Critical patent/JP2024028453A/ja
Publication of JP2024028453A5 publication Critical patent/JP2024028453A5/ja
Application granted granted Critical
Publication of JP7843302B2 publication Critical patent/JP7843302B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024002413A 2018-02-17 2024-01-11 トリアルキン結合剤及び使用方法 Active JP7843302B2 (ja)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201862631683P 2018-02-17 2018-02-17
US62/631,683 2018-02-17
US201862646739P 2018-03-22 2018-03-22
US62/646,739 2018-03-22
US201862663763P 2018-04-27 2018-04-27
US62/663,763 2018-04-27
US201962790300P 2019-01-09 2019-01-09
US62/790,300 2019-01-09
JP2020543533A JP7420727B2 (ja) 2018-02-17 2019-02-15 トリアルキン結合剤及び使用方法
PCT/US2019/018232 WO2019161213A1 (en) 2018-02-17 2019-02-15 Trialkyne linking agents and methods of use

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020543533A Division JP7420727B2 (ja) 2018-02-17 2019-02-15 トリアルキン結合剤及び使用方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026056635A Division JP2026132838A (ja) 2018-02-17 2026-03-30 トリアルキン結合剤及び使用方法

Publications (3)

Publication Number Publication Date
JP2024028453A JP2024028453A (ja) 2024-03-04
JP2024028453A5 true JP2024028453A5 (cg-RX-API-DMAC10.html) 2024-10-21
JP7843302B2 JP7843302B2 (ja) 2026-04-09

Family

ID=67620056

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020543533A Active JP7420727B2 (ja) 2018-02-17 2019-02-15 トリアルキン結合剤及び使用方法
JP2024002413A Active JP7843302B2 (ja) 2018-02-17 2024-01-11 トリアルキン結合剤及び使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020543533A Active JP7420727B2 (ja) 2018-02-17 2019-02-15 トリアルキン結合剤及び使用方法

Country Status (8)

Country Link
US (1) US20250092072A1 (cg-RX-API-DMAC10.html)
EP (1) EP3752166A4 (cg-RX-API-DMAC10.html)
JP (2) JP7420727B2 (cg-RX-API-DMAC10.html)
CN (2) CN120247964A (cg-RX-API-DMAC10.html)
AU (2) AU2019220739B2 (cg-RX-API-DMAC10.html)
CA (1) CA3089276A1 (cg-RX-API-DMAC10.html)
IL (1) IL276687B2 (cg-RX-API-DMAC10.html)
WO (1) WO2019161213A1 (cg-RX-API-DMAC10.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2019000308A1 (en) 2017-07-06 2021-05-07 Arrowhead Pharmaceuticals Inc RNAi AGENTS FOR INHIBITING EXPRESSION OF ALPHA-ENaC AND METHODS OF USE
IL309955A (en) 2018-04-27 2024-03-01 Arrowhead Pharmaceuticals Inc Integrin-targeting ligands and their uses
EP3784267B1 (en) 2018-04-27 2025-11-12 Arrowhead Pharmaceuticals, Inc. Integrin targeting ligands and uses thereof
KR20210113273A (ko) 2019-01-09 2021-09-15 애로우헤드 파마슈티컬스 인코포레이티드 HIF-2 알파 (EPAS1)의 발현을 억제하기 위한 RNAi 작용제, 그의 조성물, 및 사용 방법
JP2022535717A (ja) 2019-05-24 2022-08-10 エンピリコ インク. アンジオポエチン様7(angptl7)関連疾患の処置
IL290766B2 (en) * 2019-09-03 2026-03-01 Arcturus Therapeutics Inc Administration of therapeutically active conjugates mediated by asialoglycoprotein receptor
TW202130809A (zh) 2019-10-29 2021-08-16 美商愛羅海德製藥公司 用於抑制β-ENaC表現之RNAi藥劑、其組合物及使用方法
AU2021342155A1 (en) * 2020-09-11 2023-04-13 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of use
MX2023002939A (es) * 2020-09-11 2023-04-11 Arrowhead Pharmaceuticals Inc Plataformas para el transporte de farmacos hacia el musculo esqueletico y metodos de uso.
WO2022056269A1 (en) * 2020-09-11 2022-03-17 Arrowhead Pharmaceuticals, Inc. Skeletal muscle delivery platforms and methods of use
WO2022216920A1 (en) 2021-04-08 2022-10-13 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use
BR112023024615A2 (pt) 2021-05-28 2024-02-20 Arrowhead Pharmaceuticals Inc Agentes de rnai para inibir expressão de mucina 5ac (muc5ac), composições dos mesmos, e métodos de uso
CN113956206B (zh) * 2021-10-25 2023-04-28 深圳湾实验室坪山生物医药研发转化中心 一种用于修饰蛋白质赖氨酸残基的探针及其制备方法
US20250197859A1 (en) * 2022-03-28 2025-06-19 Empirico Inc. Compositions and methods for the treatment of angiopoietin like 7 (angptl7) related diseases
EP4499834A2 (en) * 2022-03-28 2025-02-05 Empirico Inc. Modified oligonucleotides
JP2025522433A (ja) 2022-06-15 2025-07-15 アローヘッド ファーマシューティカルズ インコーポレイテッド スーパーオキシドジスムターゼ1(SOD1)の発現を阻害するためのRNAi剤、その組成物、及び使用の方法
KR20250120424A (ko) * 2022-12-14 2025-08-08 알닐람 파마슈티칼스 인코포레이티드 간외 전달을 위한 알파-v 베타-6(αvβ6) 인테그린 리간드
MX2025014897A (es) 2023-06-13 2026-02-03 Tuojie Biotech Shanghai Co Ltd Arnip dirigido a mmp7, conjugado de arnip y su uso medico
CN121586578A (zh) 2023-08-24 2026-02-27 上海拓界生物医药科技有限公司 靶向RAGE的RNAi剂及其医药用途
TW202516008A (zh) 2023-09-27 2025-04-16 大陸商上海拓界生物醫藥科技有限公司 含三唑基化合物、製備方法及用途
IL330211A (en) 2023-12-20 2026-08-01 Arrowhead Pharmaceuticals Inc RNAi agents for inhibiting expression of activin receptor-like kinase 7 (ALK7), their compositions and methods of use
CN120309684A (zh) * 2024-01-15 2025-07-15 武汉人福创新药物研发中心有限公司 靶向化合物及其用途
WO2025212467A1 (en) 2024-03-31 2025-10-09 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of microtubule associated protein tau (mapt), compositions thereof, and methods of use
WO2025265013A2 (en) 2024-06-20 2025-12-26 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of huntingtin (htt), compositions thereof, and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7951926B2 (en) * 2006-04-28 2011-05-31 Centre National De La Recherche Scientifique (Cnrs) Method for the synthesis of oligonucleotide derivatives
GB201313201D0 (en) * 2013-07-24 2013-09-04 Univ East Anglia Virus Detection
LT3094731T (lt) * 2014-01-15 2019-10-25 Baseclick Gmbh Sacharidais modifikuotos nukleorūgšties molekulės
JP6987641B2 (ja) * 2015-05-12 2022-01-05 ブリンクバイオ インコーポレイテッド シリコン系薬物複合体及びその使用方法
AU2017296195A1 (en) * 2016-07-11 2019-01-24 Translate Bio Ma, Inc. Nucleic acid conjugates and uses thereof
TN2019000308A1 (en) * 2017-07-06 2021-05-07 Arrowhead Pharmaceuticals Inc RNAi AGENTS FOR INHIBITING EXPRESSION OF ALPHA-ENaC AND METHODS OF USE

Similar Documents

Publication Publication Date Title
JP2021502120A5 (cg-RX-API-DMAC10.html)
JP2021517113A5 (cg-RX-API-DMAC10.html)
JP2022510313A5 (cg-RX-API-DMAC10.html)
JP2023171659A5 (cg-RX-API-DMAC10.html)
JP2023113843A5 (cg-RX-API-DMAC10.html)
JP2022535911A5 (cg-RX-API-DMAC10.html)
JP2024041896A5 (cg-RX-API-DMAC10.html)
JP2023166381A5 (cg-RX-API-DMAC10.html)
JP2024529067A5 (cg-RX-API-DMAC10.html)
JP2022533069A5 (cg-RX-API-DMAC10.html)
JP2021533800A5 (cg-RX-API-DMAC10.html)
JP2022507282A5 (cg-RX-API-DMAC10.html)
JP2021517126A5 (cg-RX-API-DMAC10.html)
JP2024545787A5 (cg-RX-API-DMAC10.html)
JP2024052876A5 (cg-RX-API-DMAC10.html)
JP2008546662A5 (cg-RX-API-DMAC10.html)
JP6770511B2 (ja) 心肺障害の処置のためのスフィンゴシン−1−リン酸受容体モジュレーター
JP2025502377A5 (cg-RX-API-DMAC10.html)
JPWO2021049504A5 (cg-RX-API-DMAC10.html)
JP2024502178A5 (cg-RX-API-DMAC10.html)
RU2220140C2 (ru) Производное циклических амидов, фармацевтическая композиция и лекарственное средство, его содержащее, и способ лечения аллергического заболевания
JP2025507915A5 (cg-RX-API-DMAC10.html)
JP2007538042A5 (cg-RX-API-DMAC10.html)
JP2024501120A5 (cg-RX-API-DMAC10.html)
JP2023510865A5 (cg-RX-API-DMAC10.html)